Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases

Xi,Xun; Huang,Xing-Wei; Yuan,Huo-Zhong; He,Chun; Ni,Jun; Yang,Fu-Lan

doi:10.3892/ol.2020.12136

Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases

Authors:
- Xun Xi
- Xing-Wei Huang
- Huo-Zhong Yuan
- Chun He
- Jun Ni
- Fu-Lan Yang
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, The People's Hospital of Ganzhou, Ganzhou Affiliated Hospital of Nanchang University, Ganzhou, Jiangxi 341000, P.R. China
Published online on: September 21, 2020 https://doi.org/10.3892/ol.2020.12136
Article Number: 273
Copyright: © Xi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Whether the expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER‑2) receptor and Ki‑67 show concordance between the primary tumors and the synchronous axillary lymph node (ALN) metastases has been discussed in numerous studies. However, to date, the results of these studies remain controversial. Therefore, the present study aimed to investigate whether the expression of ER, PR, HER‑2 and Ki‑67 was in concordance between the primary tumors and synchronous ALN metastases in patients with operable breast cancer (BC). A total of 60 tissue samples were collected from patients with primary operable BC diagnosed with primary tumors and synchronous ALN metastases. The expression levels of the four biomarkers, ER, PR, HER‑2 and Ki‑67, were assessed in primary lesions and synchronous ALN metastases samples using immunohistochemistry. The cut‑off values were set to 10% for ER and PR, while the labeling index of Ki‑67 was set to 14%. The immunostaining intensity of ER and PR was scored as negative (‑), 1+, 2+ and 3+. The criteria for HER‑2 testing in BC were implemented according to the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) guidelines. The concordance rates for ER, PR and HER‑2 were 96.7 (58/60), 96.7 (58/60) and 90% (54/60), respectively. In addition, the kappa values of consistency in the primary lesions and the synchronous ALN metastases were 0.773 for ER, 0.654 for PR and 0.785 for HER‑2. Furthermore, the P‑values of ER, PR and Ki‑67 numerical variables between the two groups were 0.393, 0.400 and 0.331, respectively, as demonstrated using a non‑parametric Wilcoxon signed rank test. The findings of the present study demonstrated a high degree of concordance between the expression of ER, PR, HER‑2 and Ki‑67 in the primary tumors and that in the synchronous ALN metastases, suggesting that the BC primary tumor biomarkers may be used for the prognosis of synchronous ALN metastases in patients with operable BC.

View Figures

View References

1	Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol. 5:5–23. 2011. View Article : Google Scholar : PubMed/NCBI
2	Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
3	Gándara-Cortes M, Vázquez-Boquete Á, Fernández-Rodríguez B, Viaño P, Ínsua D, Seoane-Seoane A, Gude F, Gallego R, Fraga M, Antúnez JR, et al: Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis. Virchows Arch. 472:195–203. 2018. View Article : Google Scholar : PubMed/NCBI
4	Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and Tang P: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
5	Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010. View Article : Google Scholar : PubMed/NCBI
6	Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, et al: Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 14:324–354. 2016. View Article : Google Scholar : PubMed/NCBI
7	Mohsenifar J, Almassi-Aghdam M, Mohammad-Taheri Z, Zare K, Jafari B, Atri M, Mortazavi SH, Azadeh P, Bagherzadeh M, Azargashb E and Rahimi F: Prognostic values of proliferative markers ki-67 and repp86 in breast cancer. Arch Iran Med. 10:27–31. 2007.PubMed/NCBI
8	Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K and Stamatakos M: Correlation between Ki67 and breast cancer prognosis. Oncology. 84:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhao S, Xu L, Liu W, Lv C, Zhang K, Gao H, Wang J and Ma R: Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer. Int J Clin Exp Pathol. 8:5744–5748. 2015.PubMed/NCBI
10	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
11	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, : Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
12	Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li HY, Ren GS, Wu KN, Wang DL and Kong LQ: Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol. 31:7982014. View Article : Google Scholar : PubMed/NCBI
13	Song JL, Chen C, Yuan JP and Sun SR: Progress in the clinical detection of heterogeneity in breast cancer. Cancer Med. 5:3475–3488. 2016. View Article : Google Scholar : PubMed/NCBI
14	Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, et al: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 20:1953–1958. 2009. View Article : Google Scholar : PubMed/NCBI
15	Sari E, Guler G, Hayran M, Altundag K, Gullu I and Ozisik Y: Comparison of ER, PR, HER2 in primary and paired relapsed/metastatic lesions of metastatic breast cancer patients. J Clin Oncol. 27:10632009. View Article : Google Scholar
16	Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN and Ueno NT: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 30:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
17	Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF and Guarneri V: Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: A single-institution analysis. Ann Oncol. 24:101–108. 2013. View Article : Google Scholar : PubMed/NCBI
18	Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, et al: Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 18:667–674. 2013. View Article : Google Scholar : PubMed/NCBI
19	Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K and Tewes M; DETECT Study Group, : Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer. 16:5222016. View Article : Google Scholar : PubMed/NCBI
20	Turner N, Pestrin M, Galardi F, De Luca F, Malorni L and Di Leo A: Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel). 6:684–707. 2014. View Article : Google Scholar : PubMed/NCBI
21	Nedergaard L, Haerslev T and Jacobsen GK: Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS. 103:20–24. 1995. View Article : Google Scholar : PubMed/NCBI
22	Aitken SJ, Thomas JS, Langdon SP, Harrison DJ and Faratian D: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 21:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
23	Feng T, Zhang J and Zhong L: Relationship of ER and HER-2 expression in primary tumor and axillary lymph node metastases of invasive ductal breast cancer. Chin J Gen Surg. 2012.
24	Kinoe H, Yamanouchi K, Kuba S, Morita M, Sakimura C, Kanetaka K, Takatsuki M, Abe K, Yano H, Matsumoto M, et al: Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis. J BUON. 23:60–66. 2018.PubMed/NCBI
25	Santinelli A, Pisa E, Stramazzotti D and Fabris G: HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer. 122:999–1004. 2008. View Article : Google Scholar : PubMed/NCBI
26	Ataseven B, Gologan D, Gunesch A, Kehl V, Hoegel B, Beer M and Eiermann W: HER2/neu, topoisomerase 2a, estrogen and progesterone receptors: Discordance between primary breast cancer and metastatic axillary lymph node in expression and amplification characteristics. Breast Care (Basel). 7:465–470. 2012. View Article : Google Scholar : PubMed/NCBI
27	Jensen JD, Knoop A, Ewertz M and Laenkholm AV: ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat. 132:511–521. 2012. View Article : Google Scholar : PubMed/NCBI
28	D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O and Mingazzini PL: Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat. 101:279–284. 2007. View Article : Google Scholar : PubMed/NCBI
29	Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS and Yoo H: Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. J Neurooncol. 137:295–302. 2018. View Article : Google Scholar : PubMed/NCBI
30	Sighoko D, Liu J, Hou N, Gustafson P and Huo D: Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: Biological difference or misclassification? Oncologist. 19:592–601. 2014. View Article : Google Scholar : PubMed/NCBI